Centaur plans huge Swiss IPO

Centaur filed last week for an $89.7 million international IPO. The U.S. company will seek quotation on the Swiss stock exchange, and will not list the shares in the U.S. The company, which lost $1 million on $2.9 million in revenues in the first quarter, was mum on how many shares it planned to sell.

Centaur is developing nitrone-related therapeutics (NRTs) to treat diseases involving oxidative stress. It is conducting several Phase I trials in indications including AIDS dementia, oxidative stress-related inflammation and Parkinson's disease...